scispace - formally typeset
M

Marek Ancukiewicz

Researcher at Harvard University

Publications -  143
Citations -  20032

Marek Ancukiewicz is an academic researcher from Harvard University. The author has contributed to research in topics: Radiation therapy & Bevacizumab. The author has an hindex of 56, co-authored 142 publications receiving 18390 citations. Previous affiliations of Marek Ancukiewicz include University of Colorado Denver & Veterans Health Administration.

Papers
More filters
Journal ArticleDOI

Clinical, pharmacodynamic (PD), and pharmacokinetic (PK) evaluation of cediranib in advanced hepatocellular carcinoma (HCC): A phase II study (CTEP 7147).

TL;DR: A phase II study of cediranib (AZD2171)—a more potent and selective pan-VEGF receptor inhibitor—in advanced HCC patients, which enrolled the targeted 17 pts required for the first stage of the planned study.
Journal ArticleDOI

Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy.

TL;DR: CTCs can be used as predictors of relapse after definitive treatment of locally advanced breast cancer; however, CTCs detection in peripheral blood during the course of PC does not implicate a particular pattern of response to treatment.
Journal ArticleDOI

Modelling the relationship between continuous covariates and clinical events using isotonic regression

TL;DR: The goal of this paper is to extend isotonic regression techniques to failure time data with a continuous covariate to obtain a non-parametric estimate for the hazard of disease progression as a monotonic function of the continuous variable.
Journal ArticleDOI

An Unsupervised and Nonparametric Classification Procedure Based on Mixtures with Known Weights

TL;DR: The proposed classification method is asymptotically optimal, provided a consistent method of density estimation is used, and is applied to determining perfusion status in myocardial infarction patients, using creatine kinase measurements.
Journal ArticleDOI

Dosimetric predictors of nausea and vomiting: an exploratory analysis of a prospective phase I/II trial with neoadjuvant accelerated short-course radiotherapy and capecitabine for resectable pancreatic cancer

TL;DR: Low-dose hypofractionated radiation to the stomach is associated with nausea or vomiting during and immediately after radiotherapy, and may help identify patients who could benefit from prophylactic antiemetic medications during radiotherapy.